Senhwa Biosciences, Inc.
6492
Rank in Stocks
#19529
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Share Price
$0.90843687
Last synced: 2026-11-10
Market Cap
$103.81M
Change (1 day)
-0.67%
Change (1 year)
-30.99%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Senhwa Biosciences, Inc. (6492)
Category
Healthcare
Operating Margin for Senhwa Biosciences, Inc. (6492)
Operating Margin as of November 2026 TTM: -29,150.19%
According to Senhwa Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -29,150.19%. At the end of 2025 the company had an operating margin of -26,005.51%.
Operating Margin history for Senhwa Biosciences, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -29,150.19% | 12.09% |
| 2025 | -26,005.51% | -15.07% |
| 2024 | -30,619.10% | -1.58% |
| 2023 | -31,111.10% | -12.64% |
| 2022 | -35,611.50% | -43.44% |
| 2021 | -62,966.55% | 8.14% |
| 2020 | -58,226.74% | -55.64% |
| 2019 | -131,266.67% | 148.33% |
| 2018 | -52,860.57% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -201,574.22% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Senhwa Biosciences, Inc.'s operating margin
What is Senhwa Biosciences, Inc.'s operating margin?
Senhwa Biosciences, Inc.'s operating margin is -29,150.19%, as of Nov 2026.
What was Senhwa Biosciences, Inc.'s operating margin in 2025?
In 2025, Senhwa Biosciences, Inc.'s operating margin was -26,005.51%, compared with -30,619.10% in 2024.
How has Senhwa Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Senhwa Biosciences, Inc.'s operating margin was highest in 2025 (-26,005.51%) and lowest in 2021 (-62,966.55%).
How does Senhwa Biosciences, Inc.'s operating margin compare with similar companies?
Senhwa Biosciences, Inc.'s operating margin (-29,150.19%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.